A. Varrone

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A Varrone, A. Varrone, Andrea. Varrone, Andrea Varrone
Publication record
258 papers · 9,516 citations · H-index 53

PAPERS

Test-retest properties of [11C]PXT012253 as a positron emission tomography (PET) radiotracer in healthy human brain: PET imaging of mGlu4
20250 citationsauthor #10
Results of the first-in-human, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study of BIIB113 in healthy volunteers
20255 citationsauthor #14
A [11C]PBR28 PET study on the associations between sleep dimensions and neuroinflammation
20240 citationsauthor #4
Exploring the Interactions between two Ligands, UCB-J and UCB-F, and Synaptic Vesicle Glycoprotein 2 Isoforms
20241 citationsauthor #3
Spinocerebellar ataxia type 4 is caused by a GGC expansion in the ZFHX3 gene and is associated with prominent dysautonomia and motor neuron signs
202413 citationsauthor #12
Striatal dopamine transporter and receptor availability correlate with relative cerebral blood flow measured with [11C]PE2I, [18F]FE-PE2I and [11C]raclopride PET in healthy individuals
20230 citationsauthor #9
Longitudinal DAT changes measured with [18F]FE-PE2I PET in patients with Parkinson’s disease; a validation study
20239 citationsauthor #7
[18F]FE-PE2I DAT correlates with Parkinson’s disease duration, stage, and rigidity/bradykinesia scores: a PET radioligand validation study
202312 citationsauthor #6
Brain exposure of osimertinib in patients with EGFRm NSCLC and brain metastases: a PET and MRI study.
20235 citationsauthor #3
Brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non‐small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study
20231 citationsauthor #3
Microsome Mediated in Vitro Metabolism: A Convenient Method for the Preparation of the PET Radioligand Metabolite [18F]FE-PE2I-OH for Translational Dopamine Transporter Imaging
20230 citationsauthor #8
Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double‐Blind, Multicenter Phase 1 Trial
202325 citationsauthor #31
Spinocerebellar ataxia type 4 is caused by a GGC expansion in the ZFHX3 gene and is associated with prominent dysautonomia and motor neuron signs
20236 citationsauthor #12
Quantification of the purinergic P2X7 receptor with [11C]SMW139 improves through correction for brain-penetrating radiometabolites
20225 citationsauthor #16
Correction to: EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3
20229 citationsauthor #2
Associations between cognition and serotonin 1B receptor availability in healthy volunteers - A [ 11C]AZ10419369 Positron Emission Tomography study.
20221 citationsauthor #9
First-in-Human Evaluation of 18F-PF-06445974, a PET Radioligand That Preferentially Labels Phosphodiesterase-4B
202212 citationsauthor #12
Characterization of the Novel P2X7 Receptor Radioligand [3H]JNJ-64413739 in Human Brain Tissue
20229 citationsauthor #7
Synthesis and biological evaluation of a novel radioligand [11C] BIO-1790735 for detection of O-GlcNAcase (OGA) enzyme activity
20221 citationsauthor #5
PET as a Translational Tool in Drug Development for Neuroscience Compounds
202212 citationsauthor #1
P76.72 A PET and MRI Study Exploring Osimertinib Brain Exposure and Efficacy in EGFRm NSCLC CNS Metastases
20217 citationsauthor #3
EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3
2021229 citationsauthor #2
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Pet Study Using [ 11C ] PBR28 and Machine Learning Enhanced Analysis
20210 citationsauthor #5
[11C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins.
202124 citationsauthor #37
Sex correction improves the accuracy of clinical dopamine transporter imaging
202110 citationsauthor #7
PET Imaging of VMAT2 with the Novel Radioligand [18F]FE-DTBZ-d4 in Nonhuman Primates: Comparison with [11C]DTBZ and [18F]FE-DTBZ
20218 citationsauthor #5
Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [11C]PBR28 and Machine Learning Analysis
202130 citationsauthor #5
VNTR polymorphism in the SLC6A3 gene does not influence dopamine transporter availability measured by [18F]FE-PE2I PET or [123I]FP-Cit SPECT
20210 citationsauthor #8
Serotonin 1B receptor density mapping of the human brainstem using positron emission tomography and autoradiography
20212 citationsauthor #2
New PET radiopharmaceuticals for imaging CNS diseases
20210 citationsauthor #2
Dopamine transporter binding in symptomatic controls and healthy volunteers: Considerations for neuroimaging trials
20215 citationsauthor #13
Nondisplaceable Binding Is a Potential Confounding Factor in 11C-PBR28 Translocator Protein PET Studies
202011 citationsauthor #4
Simplified quantification of [18F]FE-PE2I PET in Parkinson’s disease: Discriminative power, test–retest reliability and longitudinal validity during early peak and late pseudo-equilibrium
202010 citationsauthor #7
Timing is everything: tau imaging across stages of Alzheimer's disease.
20203 citationsauthor #2
COVID-19 and the brain: impact on nuclear medicine in neurology
202021 citationsauthor #14
Brain exposure of the ATM inhibitor AZD1390 in humans - a positron emission tomography (PET) study.
202046 citationsauthor #8
EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0
2020191 citationsauthor #25
High-resolution PET imaging reveals subtle impairment of the serotonin transporter in an early non-depressed Parkinson’s disease cohort
202019 citationsauthor #7
Identification and in vitro characterization of C05-01, a PPB3 derivative with improved affinity for alpha-synuclein.
202031 citationsauthor #9
Non-displaceable binding is a potential confounding factor in 11 C-PBR28 TSPO PET studies
20204 citationsauthor #4
PET Molecular Imaging of Phosphodiesterase 10A: An Early Biomarker of Huntington's Disease Progression
202028 citationsauthor #15
Review for "Quantification of aromatase binding in the female human brain using [ 11 C]cetrozole positron emission tomography"
20200 citationsauthor #1
New approach in radiometabolite analysis of positron emission tomography (PET) radioligands; lead-shielded microextraction by packed sorbent as a tool for in vivo radiometabolite analysis of [11C]SMW139 in rat plasma.
20206 citationsauthor #4
PET imaging of beta-secretase 1 in the human brain: radiation dosimetry, quantification, and test-retest examination of [18F]PF-06684511
20205 citationsauthor #15
Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson’s disease
202012 citationsauthor #9
Dopamine transporter imaging in neurodegenerative movement disorders: PET vs. SPECT
202015 citationsauthor #2
Quantification and reliability of [11C]VC - 002 binding to muscarinic acetylcholine receptors in the human lung — a test-retest PET study in control subjects
20205 citationsauthor #6
A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer
202044 citationsauthor #1
P2.14-33 An Open-Label PET-MRI Study to Determine Brain Exposure of Osimertinib in Patients with EGFR Mutant NSCLC and CNS Metastases
20192 citationsauthor #2
Abstracts of the 27th International Isotope Society (UK group) symposium: Synthesis and applications of labelled compounds 2018
20190 citationsauthor #14
Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease
2019153 citationsauthor #40
Performance Evaluation of a High-Resolution Nonhuman Primate PET/CT System
201930 citationsauthor #11
[18F]FDG-PET/CT in Movement Disorders
20191 citationsauthor #2
Synthesis, 3H‐labelling and in vitro evaluation of a substituted dipiperidine alcohol as a potential ligand for chemokine receptor 2
20191 citationsauthor #6
Application of advanced brain positron emission tomography–based molecular imaging for a biological framework in neurodegenerative proteinopathies
201910 citationsauthor #24
In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [18F]MNI-659.
20196 citationsauthor #3
Effects of age, BMI and sex on the glial cell marker TSPO — a multicentre [11C]PBR28 HRRT PET study
2019100 citationsauthor #22
Increased Brain Exposure of an Alpha-Synuclein Fibrillization Modulator by Utilization of an Activated Ester Prodrug Strategy.
20189 citationsauthor #8
ABC transporter-dependent brain uptake of the 5-HT 1 B receptor radioligand [ C-11 ] AZ 10419369
20180 citationsauthor #3
Nigrostriatal dopamine transporter availability in early Parkinson's disease
201891 citationsauthor #6
PET imaging of [11C]PBR28 in Parkinson’s disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding
201852 citationsauthor #7
Blood Flow Dependence of Early [C-11]PE2I and [F-18]FE-PE2I PET SUVR Measurements Used In the Differential Diagnosis of Parkinsonian Disorders
20181 citationsauthor #7
Dual tracer tau PET imaging reveals different molecular targets for 11C-THK5351 and 11C-PBB3 in the Alzheimer brain
201837 citationsauthor #9
Dopamine transporter imaging with [18F]FE-PE2I PET and [123I]FP-CIT SPECT—a clinical comparison
201868 citationsauthor #7
SPECT Molecular Imaging in Familial Parkinson's Disease.
20184 citationsauthor #1
Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects
201812 citationsauthor #8
Abstract CT013: Osimertinib displays high brain exposure in healthy subjects with intact blood-brain barrier: a microdose positron emission tomography (PET) study with11C-labelled osimertinib
201811 citationsauthor #2
Novel Imaging Biomarkers for Huntington’s Disease and Other Hereditary Choreas
201817 citationsauthor #4
Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
201765 citationsauthor #6
Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers.
2017551 citationsauthor #18
Revisiting the Logan plot to account for non-negligible blood volume in brain tissue
20179 citationsauthor #11
Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex
201722 citationsauthor #12
Assessment of simplified ratio-based approaches for quantification of PET [11C]PBR28 data
201731 citationsauthor #4
The immune response of the human brain to abdominal surgery
2017103 citationsauthor #16
The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging
201720 citationsauthor #14
Simplified estimation of binding parameters based on image-derived reference tissue models for dopamine transporter bindings in non-human primates using [18F]FE-PE2I and PET.
20174 citationsauthor #2
[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods
201748 citationsauthor #15
Patterns of age related changes for phosphodiesterase type‐10A in comparison with dopamine D2/3 receptors and sub‐cortical volumes in the human basal ganglia: A PET study with 18F‐MNI‐659 and 11C‐raclopride with correction for partial volume effect
201726 citationsauthor #12
Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
201787 citationsauthor #5
In vivo measurement of PDE10A enzyme occupancy by positron emission tomography (PET) following single oral dose administration of PF‐02545920 in healthy male subjects
201725 citationsauthor #14
Clinical validity of presynaptic dopaminergic imaging with 123I-ioflupane and noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework.
201732 citationsauthor #7
[P2–366]: HEAD‐TO‐HEAD IN VIVO COMPARISON OF TAU‐SPECIFIC PET TRACERS IN ALZHEIMER's DISEASE: [11C]THK5351 VERSUS [11C]PBB3 PET IMAGING
20172 citationsauthor #7
Abstract # 1847 Cross-sectional and longitudinal associations between immune cells in blood and brain – A TSPO PET study in healthy control subjects
20160 citationsauthor #15
Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.
2016104 citationsauthor #20
Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes
201641 citationsauthor #7
Mapping the distribution of serotonin transporter in the human brainstem with high-resolution PET: Validation using postmortem autoradiography data
201617 citationsauthor #6
Low serotonin1B receptor binding potential in the anterior cingulate cortex in drug-free patients with recurrent major depressive disorder.
201625 citationsauthor #4
In vivo evidence of a functional association between immune cells in blood and brain in healthy human subjects.
201655 citationsauthor #13
Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls
201635 citationsauthor #19
Guidelines to PET measurements of the target occupancy in the brain for drug development
201638 citationsauthor #2
Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients
201622 citationsauthor #7
Longitudinal microPET imaging of the zQ175 mouse model of Huntington´s disease shows in vivo changes of molecular targets in the striatum and the cerebral cortex
20163 citationsauthor #12
In Vivo and In Vitro Characterization of a Novel MAO-B Inhibitor Radioligand, 18F-Labeled Deuterated Fluorodeprenyl
201670 citationsauthor #12
Movement Disorders: Focus on Parkinson’s Disease and Related Disorders
20163 citationsauthor #1
Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer’s disease and elderly controls after oral administration of sembragiline
201623 citationsauthor #6
Molecular imaging of neuroinflammation in Alzheimer’s disease
201513 citationsauthor #1
Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [18F]FEMPA in Alzheimer’s disease patients and control subjects
201575 citationsauthor #1
Amphetamine Decreases α2C-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain
201519 citationsauthor #7
Quantitative analysis of F-FE-PE2I binding to the dopamine transporter in Parkinson’s disease
20150 citationsauthor #10
Optimal acquisition time window for quantification of dopamine transporter availability with [18F]FE-PE2I in controls and PD patients
20150 citationsauthor #7

TIMELINE

1995 19 citations

1996 22 citations

1998 146 citations

1999 22 citations

2000 18 citations

2001 222 citations

2002 56 citations

2003 45 citations

2004 130 citations

2006 300 citations

2007 134 citations

2008 283 citations

2009 1,856 citations

2010 697 citations

2011 361 citations

2012 573 citations

2013 685 citations

2014 315 citations

2015 674 citations

2016 436 citations

2017 1,025 citations

2018 302 citations

2019 303 citations

2020 451 citations

2021 315 citations

2022 49 citations

2023 58 citations

2024 14 citations

2025 5 citations

A. Varrone

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT